These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18928727)

  • 1. [Rosiglitazone in two patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer: preliminary results].
    Martín T; Torres A; Cambil T; Castro J
    Med Clin (Barc); 2008 Oct; 131(11):435. PubMed ID: 18928727
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.
    Kebebew E; Peng M; Reiff E; Treseler P; Woeber KA; Clark OH; Greenspan FS; Lindsay S; Duh QY; Morita E
    Surgery; 2006 Dec; 140(6):960-6; discussion 966-7. PubMed ID: 17188145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer.
    Kebebew E; Lindsay S; Clark OH; Woeber KA; Hawkins R; Greenspan FS
    Thyroid; 2009 Sep; 19(9):953-6. PubMed ID: 19678746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone.
    Elias AN; Lizotte P
    Clin Nucl Med; 2006 Sep; 31(9):517-9. PubMed ID: 16921272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma.
    Tepmongkol S; Keelawat S; Honsawek S; Ruangvejvorachai P
    Thyroid; 2008 Jul; 18(7):697-704. PubMed ID: 18630997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by ¹²⁴I PET/CT imaging.
    Rosenbaum-Krumme SJ; Freudenberg LS; Jentzen W; Bockisch A; Nagarajah J
    Clin Nucl Med; 2012 Mar; 37(3):e47-52. PubMed ID: 22310270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
    Muros MA; Llamas-Elvira JM; Ramírez-Navarro A; Gómez MJ; Rodríguez-Fernández A; Muros T; López de la Torre M; Becerra A; Carreras JL
    Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers.
    Philips JC; Petite C; Willi JP; Buchegger F; Meier CA
    Nucl Med Commun; 2004 Dec; 25(12):1183-6. PubMed ID: 15640776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
    Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral axillary and infrahilar nodal metastases in follicular variant of papillary thyroid carcinoma (transformed into poorly differentiated subtype) in the setting of elevated thyroglobulin and negative radioiodine scintigraphy.
    Basu S
    J Cancer Res Ther; 2016; 12(1):423-4. PubMed ID: 27072275
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study.
    Simon D; Körber C; Krausch M; Segering J; Groth P; Görges R; Grünwald F; Müller-Gärtner HW; Schmutzler C; Köhrle J; Röher HD; Reiners C
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):775-82. PubMed ID: 12029551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET scan valuable in subset of patients with negative I-131 scan, rising thyroglobulin levels in differentiated thyroid cancer patients.
    Ramakant P; Verma AK
    World J Surg; 2008 Dec; 32(12):2742, author reply 2743. PubMed ID: 18685889
    [No Abstract]   [Full Text] [Related]  

  • 16. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma?
    Ronga G; Fiorentino A; Paserio E; Signore A; Todino V; Tummarello MA; Filesi M; Baschieri I
    J Nucl Med; 1990 Nov; 31(11):1766-71. PubMed ID: 2121913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
    Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
    Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
    Ong SC; Ng DC; Sundram FX
    Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma.
    Giovanella L; Ceriani L; Ghelfo A; Keller F
    Clin Chem Lab Med; 2005; 43(8):843-7. PubMed ID: 16201895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone.
    Rudavsky AZ; Freeman LM
    J Clin Endocrinol Metab; 1997 Jan; 82(1):11-4. PubMed ID: 8989223
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.